» Articles » PMID: 39184920

Molecular Signature of MiR-34a/NEAT-1/p53 Axis in Mycosis Fungoides

Overview
Publisher Wiley
Specialty Dermatology
Date 2024 Aug 26
PMID 39184920
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Mycosis fungoides (MF) is a type of cutaneous T-cell lymphoma where red rash exists on the skin. Understanding the role of miRNAs and ncRNAs in p53-response has become an open discussion, as they can regulate p53 or its downstream targets, and ncRNAs themselves.

Objectives: To evaluate the serum levels of NEAT-1, miR-34a, and p53 in MF patients and its relation to healthy controls to indicate whether it has a potential role in the pathogenesis of the disease. . This prospective case-control study was carried out on 75 subjects subdivided into two groups, 35 MF patients (stages 1 and II) and 40 matched healthy controls. Their clinical investigations and serum biomarkers (NEAT-1, miR-34a, and p53) were measured.

Results: There were significant elevations in the expression levels of both NEAT-1 (5.10 ± 1.16) and p53 (277.28 ± 62.02) in the serum of MF patients in comparison with controls (1.01 ± 0.031) and (194.29 ± 16.039), respectively, while the level of miR-34a tends to decrease in MF patients (0.24 ± 0.15). There are no significant difference between MF stages and the level of miR-34a, while in NEAT-1 and p53, there are significant differences with value <0.05 between the stages and the biomarkers. There is a positive correlation between the %BSA and miR-34a and a slightly positive correlation between NEAT-1 and P53 with ( = 0.353, =0.037) and ( = 0112, =0.05), respectively. There were also negative correlations between disease duration and NEAT-1 with ( = -0.341, =0.045) and between B2 microglobulin level and p53 ( = -0.373, =0.027).

Conclusion: The combination of miR-34a, NEAT-1, and p53 may be considered as potential biomarkers that play an active role in the disease process of MF for helping in its early diagnosis and stage identification as well.

References
1.
Hernandez Borrero L, El-Deiry W . Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting. Biochim Biophys Acta Rev Cancer. 2021; 1876(1):188556. PMC: 8730328. DOI: 10.1016/j.bbcan.2021.188556. View

2.
Balogh G, Mailo D, Nardi H, Corte M, Vincent E, Barutta E . Serological levels of mutated p53 protein are highly detected at early stages in breast cancer patients. Exp Ther Med. 2012; 1(2):357-361. PMC: 3445953. DOI: 10.3892/etm_00000056. View

3.
Manso R, Martinez-Magunacelaya N, Erana-Tomas I, Monsalvez V, Rodriguez-Peralto J, Ortiz-Romero P . Mycosis fungoides progression could be regulated by microRNAs. PLoS One. 2018; 13(6):e0198477. PMC: 5997347. DOI: 10.1371/journal.pone.0198477. View

4.
Niderla-Bielinska J, Jankowska-Steifer E, Wlodarski P . Non-Coding RNAs and Human Diseases: Current Status and Future Perspectives. Int J Mol Sci. 2023; 24(14). PMC: 10380467. DOI: 10.3390/ijms241411679. View

5.
Zhang J, Li Y, Dong M, Wu D . Long non-coding RNA NEAT1 regulates E2F3 expression by competitively binding to miR-377 in non-small cell lung cancer. Oncol Lett. 2017; 14(4):4983-4988. PMC: 5649529. DOI: 10.3892/ol.2017.6769. View